Novel small molecule induces p53-dependent apoptosis in human colon cancer cells

Biochemical and Biophysical Research Communications

Volumn 358, Issue 3, 2007, Pages 842-847

  Park, Sang Eun ^a   Min, Yong Ki ^a   Ha, Jae Du ^a   Kim, Bum Tae ^a   Lee, Woo Ghil ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Antitumor agent; Apoptosis; High throughput screening; p53; Topoisomerases II

Indexed keywords

2 (3 (2 (PYRROLIDIN 1 YL)ETHOXY) 1 10B DIHYDRO [1,2,4]TRIAZOLO[1,5 C]QUINAZOLIN 5(6H) ONE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA TOPOISOMERASE (ATP HYDROLYSING); PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL NUCLEUS; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; PHOSPHORYLATION; QUINAZOLINONES; TRANS-ACTIVATION (GENETICS); TRIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34249066079     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.04.196     Document Type: Article

References (18)

1. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
2. Nigro J.M., Baker S.J., Preisinger A.C., Jessup M.J., Hosteller R., Cleary K., Signer S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weslon A., Modali R., Harris C.C., and Vogelstein B. Mutations in the p53 gene occur in diverse human tumor types. Nature 342 (1989) 705-708
3. Gartenhaus R.B., Wang P., and Hoffmann P. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc. Natl. Acad. Sci. USA 93 (1996) 265-268
4. Liu Z.G., Baskaran R., Lea-Chou E.T., Wood L.D., Chen Y., Karin M., and Wang J.Y. Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 384 (1996) 273-276
5. Lane D.P., and Hupp T.R. Drug discovery and p53. Drug Discov. Today 8 (2003) 347-355
6. Chen X., Ko L.J., Jayaraman L., and Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10 (1996) 2438-2451
7. Mirza A., Wu Q., Wang L., McClanahan T., Bishop W.R., Gheyas F., Ding W., Hutchins B., Hockenberry T., Kirschmeier P., Greene J.R., and Liu S S. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22 (2003) 3645-3654
8. Barak Y., Juven T., Haffner R., and Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 12 (1993) 461-468
9. Knippschild U., Milne D., Campbell L., and Meek D. p53 N-terminus-targeted protein kinase activity is stimulated in response to wild type p53 and DNA damage. Oncogene 13 (1996) 1387-1393
10. Chehab N.H., Malikzay A., Stavridi E.S., and Halazonetis T.D. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl. Acad. Sci. USA 96 (1999) 13777-13782
11. Shieh S.Y., Ikeda M., Taya Y., and Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91 (1997) 325-334
12. Saito S., Yamaguchi H., Higashimoto Y., Chao C., Xu Y., Fornace Jr. A.J., Appella E., and Anderson C.W. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J. Biol. Chem. 278 (2003) 37536-37544
13. Dumaz N., and Meek D.W. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18 (1999) 7002-7010
14. Sohn T.A., Bansal R., Su G.H., Murphy K.M., and Kern S.E. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis 23 (2002) 949-957
15. Szak S.T., Mays D., and Pietenpol J.A. Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol. 21 (2001) 3375-3386
16. Cliby W.A., Roberts C.J., Cimprich K.A., Stringer C.M., Lamb J.R., Schreiber S.L., and Friend S.H. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 17 (1998) 159-169
17. Davies S.M., Robson C.N., Davies S.L., and Hickson I.D. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J. Biol. Chem. 263 (1988) 17724-17729
18. Demarquay D., Huchet M., Coulomb H., Lesueur-Ginot L., Lavergne O., Camara J., Kasprzyk P.G., Prevost G., and Bigg D.C. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo. Cancer Res. 64 (2004) 4942-4949